Study Metrics
Total Sample
6335
Treatment Group
185
Control Group
6150
Covariates
25
PICO Comparisons
2
Quality Indicators
Transparency
High
DAG Usage
No
QBA Performed
No
Study Information
| First Author: | Petito |
| Publication Year: | 2020 |
| DOI: | https://doi.org/10.1001/jamanetworkopen.2020.0452 |
| Preprint: | No preprint |
Institution & Funding
| Institutions: | Academia: Harvard T.H. Chan School of Public Health, Brown University, Feinberg School of Medicine-Northwestern University, Massachusetts General Hospital, Harvard Medical School Government: National Cancer Institute Industry: RTI Health Solutions |
| Funding: | Declared: Public, research institute, NGO |
| Funding Institutions: | This work was supported by the US National Cancer Institute contract HHSN261201700047 and grant P01-CA134294 (to Drs Petito, García-Albéniz, Logan, and Hernán), and by Patient-Centered Outcomes Research Institute awards ME-1306-03758 and ME-1502-27794 (to Dr Dahabreh). The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; by the Surveillance, Epidemiology and End Results Program of the National Cancer Institute under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute; and by the National Program of Cancer Registries from the Centers for Disease Control and Prevention under agreement U58DP003862-01 awarded to the California Department of Public Health. |
Study Context
| Disease: | Colorectal and pancreatic cancer |
| Disease Category: | Oncology |
| Data Type: | Other |
| Number of Data Sources: | 1 |
| Geography: | US |
| Eligible Sample: | 9549.0 |
Analytical Methods
| Matching Method: | IPTW |
| Analysis Method: | Cox PH |
| Estimand: | PP |
Quality Methods
Directed Acyclic Graph (DAG)
Not Used
Quantitative Bias Analysis (QBA)
Not Performed
Target Trial Information
| Target Trial Name: | QUASAR |
| Target Trial DOI: | https://doi.org/10.1016/S0140-6736(07)61866-2 |
TTE vs RCT Comparisons
Detailed comparison between Target Trial Emulation results and corresponding Randomized Controlled Trial outcomes.
Overall survival
QUASAR
HR
Efficacy
Population
patients with stage II colorectal cancer
Intervention
fluorouracil initiation within 3 months of tumor resection
Comparison
no fluorouracil initiation
Outcome
Overall survival
RCT Result
1.02
95% CI: [0.70, 1.48]
vs
TTE Result
1.01
95% CI: [0.97, 1.05]
Concordance Assessment
Confidence Interval Overlap:
Yes
CIs overlap, suggesting concordance
CIs overlap, suggesting concordance
Direction Agreement:
Same Direction
Both point to similar conclusion
Both point to similar conclusion
Overall survival
NCIC CTG PA.3
HR
Efficacy
Population
patients with advanced pancreatic adenocarcinoma
Intervention
erlotinib initiation within 12 weeks of gemcitabine
Comparison
no erlotinib initiation
Outcome
Overall survival
RCT Result
0.96
95% CI: [0.74, 1.24]
vs
TTE Result
1.03
95% CI: [0.96, 1.09]
Concordance Assessment
Confidence Interval Overlap:
Yes
CIs overlap, suggesting concordance
CIs overlap, suggesting concordance
Direction Agreement:
Different Direction
Different conclusions
Different conclusions
Transparency Indicators
Protocol Registration
Available
Data Sharing
Not Available
Code Sharing
Not Available
Overall Transparency Score:
High Transparency - This study meets good transparency standards.
Conflicts & Funding
| Conflicts of Interest: | Declared: Financial |
| COI Institutions: | Sanofi Pasteur |
| Funding Source: | Declared: Public, research institute, NGO |
| Funding Institutions: | This work was supported by the US National Cancer Institute contract HHSN261201700047 and grant P01-CA134294 (to Drs Petito, García-Albéniz, Logan, and Hernán), and by Patient-Centered Outcomes Research Institute awards ME-1306-03758 and ME-1502-27794 (to Dr Dahabreh). The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; by the Surveillance, Epidemiology and End Results Program of the National Cancer Institute under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute; and by the National Program of Cancer Registries from the Centers for Disease Control and Prevention under agreement U58DP003862-01 awarded to the California Department of Public Health. |